CPT code 86807 represents an immunogenetic laboratory screening that quantifies the percent reactive antibody in a transplant recipient's serum against potential donor human leukocyte antigens (HLA). This test is a key pre-transplant compatibility assessment used to identify recipients at elevated risk of donor-specific immune reactions and potential graft rejection. Nationally, HLA antibody screening influences transplant candidacy decisions, organ allocation considerations, and perioperative planning for immunosuppression.

Key payers covered in the discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise overview of clinical context and billing characteristics for CPT code 86807, plus practical benchmarking points relevant to laboratory and transplant programs.

Readers will learn what CPT code 86807 denotes clinically, where the service is typically performed, and which major payers are relevant for coverage considerations. The article summarizes available benchmarks and policy-relevant points in a national context and highlights areas where data was not provided. Data not available in the input is clearly noted; the focus remains on clarifying the clinical purpose and billing identity of the code for administrators, laboratory directors, and revenue cycle staff.